General Information of Drug (ID: DM2FJE7)

Drug Name
NDI-034858 Drug Info
Synonyms
Zasocitinib; NDI-034858; C293MNS6TQ; 2272904-53-5; UNII-C293MNS6TQ; TAK-279; Pyrazolo(1,5-a)pyrimidine-3-carboxamide, N-((1R,2R)-2-methoxycyclobutyl)-7-(methylamino)-5-((2-oxo(1(2H),2'-bipyridin)-3-yl)amino)-; (8S)-N-[(1R,2R)-2-methoxycyclobutyl]-7-(methylamino)-5-{[(1P,2'P)-2-oxo-2H-[1,2'-bipyridin]-3-yl]amino}pyrazolo[1,5-a]pyrimidine-3-carboxamide; N-((1R,2R)-2-Methoxycyclobutyl)-7-(methylamino)-5-((2-oxo-2H-[1,2'-bipyridin]-3-yl)amino)pyrazolo[1,5-a]pyrimidine-3-carboxamide; zasocitinib [INN]; TAK279; SCHEMBL20678921; GTPL12155; BDBM424361; EX-A7221; NDI034858; US10508120, Compound I-816; US10508120, Compound I-908; MS-28444; HY-150096; CS-0609920; compound I-908 [US20190256519A1]; F96153; N-[(1R,2R)-2-methoxycyclobutyl]-7-(methylamino)-5- [(2-oxo[1(2H),2'-bipyridin]-3-yl)amino]-pyrazolo[1,5- a]pyrimidine-3-carboxamide; N-[(1R,2R)-2-methoxycyclobutyl]-7-(methylamino)-5-[(2-oxo-1-pyridin-2-ylpyridin-3-yl)amino]pyrazolo[1,5-a]pyrimidine-3-carboxamide; ZSB
Indication
Disease Entry ICD 11 Status REF
Psoriatic arthritis FA21 Phase 2 [1]
Cross-matching ID
PubChem CID
137441492
TTD Drug ID
DM2FJE7

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Drug(s) Targeting TYK2 tyrosine kinase (TYK2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Deucravacitinib DMAR1YS Plaque psoriasis EA90.0 Approved [3]
PF-06700841 DMMGSFV Asthma CA23 Phase 2 [3]
PF-06826647 DM5H8V1 Plaque psoriasis EA90.0 Phase 2 [3]
PF-06826647 DM5H8V1 Plaque psoriasis EA90.0 Phase 2 [4]
Pyrazolo[4,3-c]pyridine derivative 2 DMCDFLQ N. A. N. A. Patented [5]
PMID27774824-Compound-Figure9Example2down DMXAV42 N. A. N. A. Patented [5]
Aminotriazolopyridine derivative 1 DMW2LZ0 N. A. N. A. Patented [5]
Imidazo[4,5-c]pyridine derivative 2 DMFDRJT N. A. N. A. Patented [5]
PMID27774824-Compound-Figure11Example1up DMH1W8F N. A. N. A. Patented [5]
Imidazo[4,5-c]pyridine derivative 1 DM4KBZQ N. A. N. A. Patented [5]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
TYK2 tyrosine kinase (TYK2) TTBYWP2 TYK2_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT05153148) A Phase 2b, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Subjects With Active Psoriatic Arthritis. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of Nimbus Therapeutics
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases. J Med Chem. 2020 Nov 25;63(22):13561-13577.
5 Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.